# Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study

> **NCT00445913** · PHASE1 · COMPLETED · sponsor: **University of Pittsburgh** · enrollment: 10 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **BIOLOGICAL:** Diabetes-suppressive dendritic cell vaccine
- **BIOLOGICAL:** control dendritic cells

## Key facts

- **NCT ID:** NCT00445913
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2012-01
- **Final completion:** 2016-02
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2016-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00445913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00445913, "Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00445913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*